Asian stocks pared declines, with Japanese shares reversing losses, after the Bank of Japan (8301) expanded its stimulus program in its first policy decision under new governor Haruhiko Kuroda.
Toyota Motor Corp., the world�� largest carmaker, advanced 2.8 percent, reversing an earlier drop, as the yen weakened against the dollar and Japanese government bonds rose. Mitsubishi Estate Co. (TPREAL) surged 7.2 percent in Tokyo, leading gains among property firms. BHP Billiton Ltd., the world�� No. 1 miner, retreated 1.5 percent in Sydney as copper sank to the lowest price since August.
The MSCI Asia Pacific Index (MXAP) slid 0.6 percent to 134.11 as of 6:05 p.m. in Tokyo, paring a loss of as much as 1.1 percent. Japan�� Topix Index reversed declines of as much as 2 percent to close 2.7 percent higher after the central bank said it will double monthly bond purchases in a bid to reach 2 percent inflation in two years. Markets in China, Hong Kong and Taiwan are closed today for a holiday.
Top 5 Construction Material Companies To Own For 2015: 22nd Century Group Inc (XXII)
22nd Century Group, Inc. (22nd Century Group), incorporated on September 12, 2005, is a holding company. The Company�� wholly owned subsidiary, 22nd Century Limited, LLC (22nd Century Ltd), which is a plant biotechnology company. The Company�� products include X-22 Smoking Cessation Aid, Modified Risk Cigarettes, BRAND A Cigarettes and BRAND B Cigarettes. On January 25, 2011, 22nd Century Limited, LLC (22nd Century Ltd) completed a reverse merger transaction (the Merger) with 22nd Century Group, and as a result, 22nd Century Ltd became a wholly owned subsidiary of 22nd Century Group, which continues to operate the business of 22nd Century Ltd. the Company�� drug application for X-22 was cleared by the United States Food and Drug Administration (FDA) in July 2011. The Company�� subsidiary, Goodrich Tobacco Company, LLC (Goodrich Tobacco), had introduced two cigarette brands, RED SUN and MAGIC, into the United States marketed during the year ended December 31, 2011. In December 2013, 22nd Century Group Inc acquired an undisclosed manufacturing facility located in Mocksville, North Carolina. Effective December 11, 2013, 22nd Century Group Inc acquired NASCO Specialty Brands LLC.
X-22 is a tobacco-based botanical medical product for use as a smoking cessation therapy. X-22 is a prescription-only kit consists of very low nicotine (VLN) cigarettes made from its tobacco. The therapy protocol allows the patient to smoke its VLN cigarettes without restriction over the six-week treatment period to facilitate the goal of the patient quitting smoking by the end of the treatment period. In 2011, Biotech Crops were planted in 29 countries on 395 million acres (160 million hectares).
The Company competes with Pfizer Inc., GlaxoSmithKline PLC, Novartis International AG, Reynolds American Inc, Philip Morris USA Inc., Reynolds American Inc., Lorillard Inc., Commonwealth Brands, Inc., Liggett Group LLC, Vector Tobacco Inc., Star Scientific Inc, Philip Morris International Inc., British! American Tobacco, JT International SA, Imperial Tobacco Group PLC and China National Tobacco Corporation.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Chromadex Corp (OTCMKTS: CDXC) and 22nd Century Group Inc (OTCBB: XXII) are, one way or the other, focused on natural products and have been getting some extra attention lately. Moreover, one of these stocks have been the subject of a disclosed investor awareness campaign. Keeping that in mind, are these two small cap stocks natural winners for investors? Here is a quick look:
Hot Asian Companies To Buy Right Now: Arc Wireless Solutions Inc.(ARCW)
ARC Wireless Solutions, Inc., together with its subsidiaries, provides wireless network components and solutions in the United States. It is involved in the design, development, manufacture, marketing, and sale of antennas and related wireless communication systems, including cellular base stations, mobiles, cellulars, and flat panel antennas. The company?s products also include global positioning systems; and conformal, portable, and other antennas, as well as antenna accessories. ARC Wireless Solutions, Inc. markets its commercial line of antennas directly to distributors, installers, and retailers of antenna accessories, as well as to commercial, government, and retail markets. It offers its products under the Freedom Antenna Exsite, Omnibase, Parity, Arc Vlpa, Airbase, and And Freedom Blade brand names. The company was formerly known as Antennas America, Inc. and changed its name to ARC Wireless Solutions, Inc. in October 2000. ARC Wireless Solutions, Inc. was founded in 1987 and is based in Denver, Colorado.
Advisors' Opinion:- [By Jake L'Ecuyer]
Meanwhile, top decliners in the sector included ARC Group Worldwide (NASDAQ: ARCW), down 6.8 percent, and 8x8 (NASDAQ: EGHT), off 5.7 percent.
Top Headline
Apple (NASDAQ: AAPL) is in talks to acquire headphone maker Beats Electronics, according to a Financial Times report from Thursday afternoon. The deal is rumored to be around $3.2 billion, which would make it Apple's largest acquisition to date.
Hot Asian Companies To Buy Right Now: Gyrodyne Company of America Inc.(GYRO)
Gyrodyne Company of America, Inc., a real estate investment trust (REIT), engages in the investment, acquisition, ownership, and management of a portfolio of medical office and industrial properties in the northeast region of the United States. The company also involves in the development of industrial and residential properties. It focuses on acquiring, developing, owning, leasing, and managing medical, commercial, and industrial real estate. The company has elected to be taxed as REIT under the Internal Revenue Code. As a REIT, it would not be subject to federal income tax purposes, provided that it distributes at least 90% of its taxable income to its shareholders. The company was founded in 1946 and is headquartered in St. James, New York.
Advisors' Opinion:- [By Geoff Gannon] >Syms (SYMSQ) where at some point the company�� entire value really depended on its balance sheet.
Obviously when looking at things like real estate you don�� go by what it says on the balance sheet. You try to find a note on depreciation that breaks out land, buildings, etc. And gives information about how the company depreciates its property.
And ��of course ��you look at the ��roperties��item in the 10-K. In the U.S., you then use the information you��e gathered to check county land records and things like that for more information about the property.
Generally, you want to:
路 Find out when the company bought the property
- [By Lisa Levin]
Gyrodyne Co. of America (NASDAQ: GYRO) shares dipped 8.66% to reach a new 52-week low of $10.86. Gyrodyne Co. of America's trailing-twelve-month ROA is -5.29%.
- [By Sally Jones]
Highlight: Gyrodyne Company of America (GYRO)
The GYRO share price is currently $73.85 or 35.7% off the 52-week high of $114.80. The company does not pay a dividend.
Hot Asian Companies To Buy Right Now: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion:- [By Jake L'Ecuyer]
Top Headline
Forest Laboratories (NYSE: FRX) announced its plans to buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion. Forest will pay around $95 per share, or around $1.1 billion in cash. Forest Labs will also pay up to $30 per share, or around $360 million in a contingent value right. The deal is projected to close in the second or third quarter of 2014. - [By Dan Caplinger]
Several other companies use similar strategies to cut their tax bills in high-tax jurisdictions. Google (NASDAQ: GOOG ) has used units based in Ireland and the Netherlands to help greatly reduce taxation on the money it earns, while Professor Edward Kleinbard's recent paper "Through a Latte, Darkly" goes into great detail about the methods that Starbucks (NASDAQ: SBUX ) used to minimize tax payments to the U.K. through the use of affiliates in the U.S., the Netherlands, and Switzerland. A Bloomberg article from 2011 cited Forest Labs (NYSE: FRX ) as using a strategy similar to Google's involving an Irish unit headquartered in Bermuda, while the same article said Cisco Systems (NASDAQ: CSCO ) attributed half its profits to a unit in Rolle, Switzerland.
- [By Ben Levisohn]
Investors sure aren’t acting like it, despite the major indexes mixed results. Forest Laboratories (FRX) gained 16% to $69 this week after it purchased another pharmaceutical company, while Constellation Brands (STZ) rose 15% to $80.05 after besting its earnings forecasts. Intuitive Surgical (ISRG) rose after a study found fewer complications from “robotic-assisted” prostate removal surgery.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Tuesday’s session are Forest Laboratories Inc.(FRX), Coca-Cola Co.(KO) and Waste Management Inc.(WM)
Hot Asian Companies To Buy Right Now: IRSA Inversiones Y Representaciones S.A. (IRS)
IRSA Investments and Representations Inc., through its subsidiaries, engages in a range of diversified real estate investment and related activities in Argentina. The company is involved in the acquisition, development, and operation of shopping centers, offices, and other non-shopping center properties primarily for rental purposes; development and sale of residential properties; acquisition and operation of luxury hotels; and acquisition of undeveloped land reserves for future development purpose. It also engages in consumer financing activities, including credit card products to its consumers at shopping centers, hypermarkets, and street stores. IRSA Investments and Representations, Inc. was founded in 1943 and is headquartered in Buenos Aires, Argentina.
Advisors' Opinion:- [By Garrett Cook]
In trading on Wednesday, financial shares were relative laggards, down on the day by about 0.24 percent. Top losers in the sector included IRSA Investments and Representations (NYSE: IRS), down 3.2 percent, and OceanFirst Financial (NASDAQ: OCFC), off 2.5 percent.
Hot Asian Companies To Buy Right Now: Fortis Inc (FRTSF.PK)
Fortis Inc. (Fortis) is an investor-owned gas and electric distribution utility in Canada. Its regulated utilities account for 90 % of total assets and serve customers across Canada and in New York State and the Caribbean. Fortis owns non-regulated hydroelectric generation assets in Canada, Belize and Upstate New York. The Company's non-utility investments are comprised of hotels and commercial real estate in Canada and petroleum supply operations in the Mid-Atlantic Region of the United States. Advisors' Opinion:- [By Markus Aarnio]
Emera's competitors include Northland Power (NPIFF.PK), Fortis (FRTSF.PK), and Atlantic Power (AT). Northland Power has seen insider buying in August and has a dividend yield of 7.6%. Fortis has seen both insider buying and insider selling in August. Fortis has a dividend yield of 4.1%. Atlantic Power saw insider buying last time in April. Atlantic Power has a dividend yield of 9.4%.
No comments:
Post a Comment